Fermenta Biotech Ltd · BSE:FERMENTA
Fermenta Biotech — Q2 FY2025 Earnings Presentation
19 slides from Fermenta Biotech's earnings presentation, Nov 18, 2024
Slide 1: Intimation of Earnings Presentation to BSE
Ref: F.No.:908 November 18, 2024 Corporate Relations BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Dear Sir, Sub.: Intimation of Earnings Presentation for Quarter 2 of Financial Year (‘FY’) 2024-25 [Q2-FY25] Ref: Scrip Code: 506414 Further to our intimation dated Novem
Slide 2: Earnings Presentation | Q2/H1-FY25
Earnings Presentation | Q2/H1-FY25
Slide 3: Snapshot
Snapshot Top 3 Only manufacturer of Amongst top 3 manufacturers Global Presence in Vitamin D3 in India of Vitamin D3 globally 60+ countries Proprietary technology to 55 Years of Vitamin D3 Both manufacturing facilities certified manufacture Vitamin D3 manufacturing experience by global regulatory bo
Slide 4: Company Overview
Company Overview • Fermenta Biotech Limited (FBL) (Erstwhile DIL Ltd.) incorporated in 1951 by Dr. DVK Raju, is engaged in development and manufacturing of pharmaceuticals, biotechnology and Consolidated Revenue (INR Mn) & EBITDA Margins (%) environmental solutions used across various industries. 3,
Slide 5: Q2/H1-FY25 Financial Overview
Q2/H1-FY25 FINANCIAL OVERVIEW
Slide 6: Q2/H1-FY25 Financial Highlights
Q2/H1-FY25 Financial Highlights Q2-FY25 Standalone Performance H1-FY25 Standalone Performance INR 895 Mn INR 156 Mn 17.43% INR 1,622 Mn INR 173 Mn 10.67% Operational Income Operational EBITDA Operational EBITDA Margin Operational Income Operational EBITDA Operational EBITDA Margin INR 82 Mn 9.16% IN
Slide 7: Q2/H1-FY25 Operational Highlights
Q2/H1-FY25 Operational Highlights • Volumes of Vitamin D3 for Human Nutrition in Q2-FY25 increased by 62% YoY and in H1-FY25 it increased by 54% YoY. • Volumes of Animal Feed in Q2-FY25 increased by 137% YoY and in H1-FY25 it increased by 33% YoY, while the average prices of Animal Feed were 3 times
Slide 8: Vitamin D3 Animal Feed Price Trend
Vitamin D3 500 Animal Feed Price Trend 85 80 75 60 Price (Euro/kg) 40 33 32 30 25 22 20 20 16 13 12 12 9 10 8 10 8 8 7 6 6 6 7 7 7 7 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Q1 2024 Q2 2024 Q3 2024 Calendar Year Source: feedinfo.com Min of Low Max of High Fermenta Biotech Limited
Slide 9: Quarterly Standalone Financial Performance
Quarterly Standalone Financial Performance PARTICULARS (INR Mn) Q2-FY25 Q2-FY24 Y-o-Y Q1-FY25 Q-o-Q Operational Revenue 895 513 74.5% 727 23.1% Total Expenses 739 629 17.5% 708 4.4% Operational EBITDA 156 (116) NA 19 NA Operational EBITDA Margins (%) 17.43% NA NA 2.61% NA Other Income 29 20 45.0% 26
Slide 10: Half Yearly Standalone Financial Performance
Half Yearly Standalone Financial Performance PARTICULARS (INR Mn) H1-FY25 H1-FY24 Y-o-Y Operational Revenue 1,622 1,281 26.6% Total Expenses 1,449 1,265 14.5% Operational EBITDA 173 16 NA Operational EBITDA Margins (%) 10.67% 1.25% 942 Bps Other Income 56 41 36.6% Depreciation 118 114 3.5% Finance C
Slide 11: Quarterly Consolidated Financial Performance
Quarterly Consolidated Financial Performance PARTICULARS (INR Mn) Q2-FY25 Q2-FY24 Y-o-Y Q1-FY25 Q-o-Q Operational Revenue 950 569 67.0% 781 21.6% Total Expenses 763 708 7.8% 773 (1.3)% Operational EBITDA 187 (139) NA 8 NA Operational EBITDA Margins (%) 19.68% NA NA 1.02% NA Other Income 29 19 52.6%
Slide 12: Half Yearly Consolidated Financial Performance
Half Yearly Consolidated Financial Performance PARTICULARS (INR Mn) H1-FY25 H1-FY24 Y-O-Y Operational Revenue 1,732 1,394 24.2% Total Expenses 1,536 1,423 7.9% Operational EBITDA 196 (29) NA Operational EBITDA Margins (%) 11.32% NA NA Other Income 57 39 46.2% Depreciation 123 119 3.4% Finance Cost 7
Slide 13: Historical Standalone Income Statement
Historical Standalone Income Statement PARTICULARS (INR Mn) H1-FY25 FY24 FY23 FY22 Operational Revenue 1,622 3,071 3,289 3,880 Total Expenses 1,449 2,701 2,905 3,120 Operational EBITDA 173 370 384 760 Operational EBITDA Margins (%) 10.67% 12.05% 11.68% 19.59% Other Income 56 82 85 75 Depreciation 11
Slide 14: Historical Consolidated Income Statement
Historical Consolidated Income Statement PARTICULARS (INR Mn) H1-FY25 FY24 FY23 FY22 Operational Revenue 1,732 3,357 3,499 3,985 Total Expenses 1,536 3,082 3,323 3,371 Operational EBITDA 196 275 176 614 Operational EBITDA Margins (%) 11.32% 8.19% 5.12% 15.41% Other Income 57 118 86 81 Depreciation 1
Slide 15: Historical Standalone Balance Sheet
Historical Standalone Balance Sheet PARTICULARS (INR Mn) H1-FY25 FY24 FY23 PARTICULARS (INR Mn) H1-FY25 FY24 FY23 Equity 3,150 3,142 3,360 Assets Non-current Assets 3,165 3,264 4,105 a) Equity share capital 145 144 144 a) Property, plant and equipment 2,291 2,364 2,048 b) Other equity 3,005 2,998 3,
Slide 16: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet PARTICULARS (INR Mn) H1-FY25 FY24 FY23 PARTICULARS (INR Mn) H1-FY25 FY24 FY23 Equity 2,860 2,851 3,126 Assets Non-current Assets 2,949 3,061 3,835 a) Equity share capital 145 144 144 a) Property, plant and equipment 2,291 2,364 2,048 b) Other equity 2,756 2,744
Slide 17: Historical Consolidated Financial Performance
Historical Consolidated Financial Performance Operational Revenue (INR Mn) Operational EBITDA (INR Mn) & Margins (%) PAT (INR Mn) & Margins (%) 154 3,985 3,499 614 52 3,357 3.86% 3.00% 15.41% FY22 FY23 FY24 H1-FY25 -7.15% 1,732 275 11.32% -240 176 8.19% 196 5.12% -15.18% -531 FY22 FY23 FY24 H1-FY25
Slide 18: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 19: Thank You
Thank You